anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: There are many scientific reports on systemic inflammation scores (SIS) associated with decreased bone mineral density in osteoporotic vertebral disease. However, there are no studies on the association of inflammation scores with the risk of collapse in osteoporotic vertebral collapse fractures. The aim of this study was to examine the correlation between the product of platelet and neutrophil counts (PPN), platelet/lymphocyte ratio (PLR), neutrophil/lymphocyte ratio (NLR), and systemic immune inflammation index (SII) derived from complete blood count analysis in cases of osteoporotic vertebral fractures and fracture severity based on vertebral collapse rates.
PATIENTS AND METHODS: This study is a retrospective analysis of a cohort of 50 patients aged 50 years or older who presented with osteoporotic vertebral fractures and underwent kyphoplasty at our clinic from 2018 to 2023. The study included both men and women. Computed tomography (CT) and magnetic resonance imaging (MRI) were used to diagnose and differentiate osteoporotic vertebral compression fractures from burst fractures and pathologic fractures. All compression rate measurements were performed with CT. The compression rate of the most affected vertebra (MAV-CR) was calculated. Groups were divided into two categories based on their compression rates: <50% and ≥50%. Initial PPN, PLR, NLR, and SII parameters were used as systemic inflammation scores.
RESULTS: No statistically significant differences were found between MAV-CR groups in PPN, PLR, NLR, and SII parameters (p>0.05). No statistically significant correlation was observed between inflammation scores and MAV-CR groups (p>0.05). In this comparison, no significant difference was observed between the selected CBC parameters and the groups divided according to the compression rate (WBC: p=0.725, PC: p=0.069, NC: p=0.732, LC: p=0.513). ROC analysis was performed to analyze the diagnostic tests (AUC=0.372 for PPN, AUC=0.509 for PLR, AUC=0.525 for NLR, and AUC=0.435 for SII). None of the systemic inflammation scores had any predictive value for osteoporotic vertebral collapse fractures.
CONCLUSIONS: Although it has been established in the scientific literature that systemic inflammation scores are associated with osteoporotic vertebral fractures, our analysis indicates no statistically significant correlation between the parameters of PPN, PLR, NLR, and SII and the severity of compression fractures in individuals with osteoporotic vertebral fractures. In this study, using systemic inflammation scores as a predictive test for the severity of osteoporotic vertebral fractures does not seem appropriate.
This trial will compare the benefits and side effects of two medications-clonidine and methylphenidate (MPH)-used alone or in combination to treat ADHD in children. MPH is FDA-approved for the treatment of ADHD symptoms in children, and clonidine is FDA-approved for the treatment of hypertension in adults. Stimulant medications such as MPH are known to be safe and effective for the treatment of many ADHD symptoms. Such medicines, however, do not cure the condition or improve all of the symptoms of ADHD, and the long-term effectiveness of these medications is not well-known. In this study the participants will be randomly selected to receive one of four treatments: 1.) clonidine; 2.) MPH; 3.) clonidine and MPH; or 4.) a placebo (which is not an active medication, but a substance that is thought to have no biological effect). The time participation in the study is 16 weeks.
PURPOSE:To obtain iron oxide pigment powder showing golden color by allowing both water-soluble salt and a compd. contg. Si to previously exist in alkali suspension incorporating ferric salt and subjecting the mixture to hydrothermal treatment. CONSTITUTION:Both 0.1-15.0mol. water-soluble salt for 1mol. Fe and a compd. incorporating 1.5-20.0mol.% of Si to 100% of Fe, expressed in terms of Si, are allowed to previously exist in alkali suspension incorporating ferric salt and having >=9pH. Then the aimed iron oxide pigment powder is obtained by subjecting this suspension to hydrothermal treatment. As the water-soluble salt, sulfate, nitrate, chloride and acetate, etc., of alkali metal are used. Furthermore, as the compd. incorporating Si, silicate of potassium and sodium and colloidal silica, etc., are used. As the reason of golden color shown by this iron oxide pigment, it is considered that both the particle form of iron oxide pigment and the surface state of the particle are concerned.
PROBLEM TO BE SOLVED: To obtain the subject composition having favorable cosmetic characteristics, causing no crystallization thereof even if stored at low temperatures by including straight-chain decamethyltetrasiloxane and more volatile solvent(s) as the volatile solvent of the fat phase. SOLUTION: This composition contains, as the volatile solvent of the fat phase, (A) straight-chain decamethyltetrasiloxane (L4) and (B) at least one kind of 2nd volatile solvent higher in evaporation rate then the component A (pref. evaporation rate ratio B/A of pref. 2.2-3, more pref. 2.4-2.8) (e.g. alkane, cycloalkane, fluorohydrocarbon, silicone, modified silicone); wherein the content of the component A in this composition is pref. 15-40 (more pref. 25-35) wt.% (when the evaporation rate ratio for the components A and B is as mentioned above).
PURPOSE: An oral formulaion containing telmisartan is provided to ensure formulation stability and to improve release profile. CONSTITUTION: A pharmaceutical composition contains insoluble drugs or pharmaceutically acceptable salt thereof, and water insoluble diluent. The insoluble drug is telmisartan. The pharmaceutical composition additionally contains alkylating agent and stabilizing agent. The alkylating agent is inorganic or organic. The stabilizing agent is cellulose derivative-based stabilizer such as hydroxypropyl cellulose, hydroxymethyl cellulose, or hydroxyethyl cellulose.
The goal of the COVID-ThromboprophylaXIs Study is to determine the safety and tolerability of two doses of frunexian (EP-7041) for the prevention of thromboembolism in the management of COVID-19 patients, compared to control patients managed with institutional standard care thromboprophylaxis regimens. Dosing of frunexian for the first 15 patients enrolled will be randomized to 0.6 mg/kg/hr IV (n=15) and next 15 patients will be randomized to 1.0 mg/kg/hr IV (n=15) for the duration of the index hospitalization. Enrollment will be paused after treatment of these 30 patients, at which time a dedicated DSMB will evaluate all collected safety data through 7 days post-index hospital discharge. If no adverse safety signal is identified for the 1.0 mg/kg/hr dose, enrollment will be resumed with the study dose of frunexian randomized 2:1 to 1.0 mg/kg/hr or institutional standard care for thromboprophylaxis in ICU patients with COVID-19. If safety concerns are identified for the higher dose and not for the lower dose, then open-label randomized enrollment vs institutional standard of care for thromboprophylaxis will proceed with an frunexian dose of 0.6 mg/kg/hr. The second phase of the study will enroll 60 additional patients, with 40 in the frunexian dosing arm, and 20 in the standard care arm.
PURPOSE:To provide an aerosol hair-dye composed of a ferrous salt, hematein, an organic solvent, a reducing agent, water and a propellant gas, capable of dyeing gray hair under mild condition, giving fast and excellently finished hair and free from the staining of clothes and pillow cover. CONSTITUTION:The objective hair-dye can be produced by mixing 0.01-20wt.% of a ferrous salt (e.g. ferrous sulfate), 0.01-5wt.% of hematein, 0.1-20wt.% of an organic solvent (e.g. N-alkylpyrrolidone), 0.01-20wt.% of a reducing agent (e.g. ascorbic acid), water and 1-20wt.% of a propellant gas, adjusting the pH of the mixture to 2-6 and filling the mixture in a sealed container in the form of aerosol essentially in the absence of oxygen by conventional filling process. Preferably, the composition is further compounded with 0.001-10wt.% of a hydroxy compound, 0.1-10wt.% of a surfactant and, as necessary, a higher alcohol, a thickener, an oil, a humectant, etc.
Amyotrophic Lateral Sclerosis (ALS): Clinical diagnosis of ALS requires the presence of UMN and LMN involvement in different body regions and evidence of progressive spread of symptoms or signs according to EEC. ALS clinic patients with suspected, possible, probable, probable-laboratory supported, or definite ALS will be included. ALS clinic participants with suspected, possible, probable, probable-laboratory supported, and definite Amyotrophic Lateral Sclerosis (ALS) according to revised El Escorial Criteria (EEC) will participate in 5 longitudinal visits; Screening/Baseline Visit 1, and four (4) follow-up visits which will occur at approximate 4-month intervals. Upon IRB approved consent, the study participant will undergo the assessments and bio-fluid collections at each visit as outlined in the Schedule of Events.
Clear cell renal cancer is a highly vascular tumor characterized by mutations in the von Hippel-Lindau (VHL) gene in the majority of patients, an alteration that leads to overexpression vascular endothelial growth factor (VEGF) as well as other genes such as transforming growth factor-alpha, platelet derived growth factor and glucose transporter 1. Patients received ZD6474 300 mg/day by mouth daily on days 1-28.
Consistent with the potentially immunogenic properties of protein and peptide pharmaceuticals, patients treated with OZEMPIC may develop anti-semaglutide antibodies. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, the incidence of antibodies to semaglutide in the studies described below cannot be directly compared with the incidence of antibodies in other studies or to other products. 

Across the placebo- and active-controlled glycemic control trials, 32 (1.0%) OZEMPIC-treated patients developed anti-drug antibodies (ADAs) to the active ingredient in OZEMPIC (i.e., semaglutide). Of the 32 semaglutide-treated patients that developed semaglutide ADAs, 19 patients (0.6% of the overall population) developed antibodies cross-reacting with native GLP-1. The in vitro neutralizing activity of the antibodies is uncertain at this time.
Chimeric antigen receptor (CAR) T-cells targeting CD19 have been approved for the treatment of relapse/refractory large B-cell lymphoma. Hematotoxicity is the most frequent CAR T-cell-related adverse event. Transfusion support is a surrogate marker of severe cytopenias. Transfusion affects patients' quality of life, presents specific toxicities, and is known to affect immunity through the so-called transfusion-related immunomodulation that may affect CAR T-cell efficacy. We analyzed data from 671 patients from the French DESCAR-T registry for whom exhaustive transfusion data were available. Overall, 401 (59.8%) and 378 (56.3%) patients received transfusion in the 6-month period before and after CAR T-cell infusion, respectively. The number of patients receiving transfusion and the mean number of transfused products increased during the 6-month period before CAR T-cell infusion, peaked during the first month after infusion (early phase), and decreased over time. Predictive factors for transfusion at the early phase were age >60 years, ECOG PS ≥2, treatment with axicabtagene ciloleucel, pre-CAR T-cell transfusions, and CAR-HEMATOTOX score ≥2. Predictive factors for late transfusion (between 1 and 6 months after infusion) were pre-CAR T-cell transfusions, CAR-HEMATOTOX score ≥2, ICANS ≥3 (for red blood cells [RBC] transfusion), and tocilizumab use (for platelets transfusion). Early transfusions and late platelets (but not RBC) transfusions were associated with a shorter progression-free survival and overall survival. Lymphoma-related mortality and nonrelapse mortality were both increased in the transfused population. Our data shed light on the mechanisms of early and late cytopenia and on the potential impact of transfusions on CAR T-cell efficacy and toxicity.
Laser Scanner (Vivid 9i® - Konica Minolta)was used to digitize the study casts. After scanning the dental casts a 3D virtual dental casts was used to realize all measurements (pre-treatment, 4 months and 10 months).
BACKGROUND: Pulmonary Fibrosis (PF) is a progressive lung disease characterized by the diffuse interstitial tissue, leading to severe breathing difficulties. The existing treatment methods are primarily aimed at slowing the progression of the disease, underscoring the urgent need to discover new drug interventions targeting novel sites. The "gut-lung axis" represents a complex bidirectional communication system where the gut microbiota not only influences lung immunity but also responds to lung-derived signals. Recent advances have uncovered that alterations in gut microbiota composition can significantly impact respiratory diseases, offering new insights into their pathogenesis and potential therapeutic approaches.
METHODS: This study is based on the fundamental concepts of the lung-gut axis and our previous research, further exploring the potential mechanisms of 20(S)-Protopanaxadiol (PPD) in ginseng against PF. We utilized a bleomycin-induced mouse model of PF and employed metabolomics and 16S rRNA sequencing to investigate the pathways through which PPD regulates the pulmonary fibrosis process via the gut-lung axis. Finally, we employed strategies such as antibiotic-induced microbiota disruption and fecal microbiota transplantation (FMT) to provide a comprehensive perspective on how PPD regulates pulmonary fibrosis through gut microbiota.
RESULTS: The results of the bleomycin (BLM) mouse model of PF proved that PPD can directly act on the glycolysis- related metabolic reprogramming process in lung and the AMPK/STING pathway to improve PF. Combined the analysis of gut microbiota and related metabolites, we found that PPD can regulate the process of PF through the gut-lung axis target points G6PD and SPHK1. FMT and antibiotic-induced microbiota disruption further confirmed intermediate effect of gut microbiota in PF process and the treatment of PPD. Our study suggests that PPD can alleviate the process of pulmonary fibrosis either by directly acting on the lungs or by regulating the gut microbiota.
CONCLUSION: This study positions PPD as a vanguard in the therapeutic landscape for pulmonary fibrosis, offering a dual mechanism of action that encompasses both modulation of gut microbiota and direct intervention at molecular targets. These insights highlight the immense therapeutic potential of harnessing the gut-lung axis.
Pregnancy Category C. Reproduction studies with dronabinol have been performed in mice at 15 to 450 mg/m2, equivalent to 0.2 to 5 times maximum recommended human dose (MRHD) of 90 mg/m2/day in cancer patients or 1 to 30 times MRHD of 15 mg/m2/day in AIDS patients, and in rats at 74 to 295 mg/m2 (equivalent to 0.8 to 3 times MRHD of 90 mg/m2 in cancer patients or 5 to 20 times MRHD of 15 mg/m2/day in AIDS patients). These studies have revealed no evidence of teratogenicity due to dronabinol. At these dosages in mice and rats, dronabinol decreased maternal weight gain and number of viable pups and increased fetal mortality and early resorptions. Such effects were dose dependent and less apparent at lower doses which produced less maternal toxicity. There are no adequate and well-controlled studies in pregnant women. Dronabinol should be used only if the potential benefit justifies the potential risk to the fetus.
Psychosis is one of the 20 leading causes of disability worldwide, affecting 29 million people. First Episode Psychosis (FEP) occurs at a young age and is thought to be a critical period, influencing the long-term course of the disorder. The early course of psychosis is characterised by repeated relapses with up to 80 % relapsing within five years of an initial episode. It has been reported that individuals diagnosed with psychosis disorders are also identified with developing experiences of self-harm, completed suicide or suicide attempt. A systematic review on identification of correlation between self-harm/suicidality and FEP, also suggested association of suicidal ideation or self-injurious behavior though additional research is highly recommended in this particular subject Psychological therapies are widely used in the high-income countries, but very limited in LMIC like Pakistan due to factors including lack of trained mental health workers and inadequate infrastructure to support secondary mental health services. These factors, amongst others, contribute to the significant treatment gap in LMICs like Pakistan. There are currently no early intervention services in Pakistan and given the shortage of appropriately trained clinicians to deliver psychosocial interventions novel approaches are needed. We have culturally adapted Cognitive Behavior therapy which demonstrated feasibility and acceptability for psychosis in Pakistan. To address suicide specific symptoms, content will be integrated from the life after self-harm manual (CMAP. It is a CBT based problem solving intervention for self-harm which has been adapted in Pakistan in a feasibility trial and a recently completed MRC funded large multicenter trial (n=901)
A barrier cream for the mitigation of burns comprises a base cream and at least one of a melt additive (a compound with a relatively high latent heat of fusion to absorb heat) and a reflective additive (a compound that can reflect radiation, preferably at infra-red and visible wavelengths). Preferably, the barrier cream comprises a melt additive and a reflective additive and the additive(s) can comprise 5-75% w/w of the barrier cream. Preferably, the melt additive is an alkali metal salt, an alcohol, a fat, a wax, a fatty acid or a derivative of a fatty acid, such as an ester and has a latent heat of fusion of at least 50 J per g and has a melting point below 55 {C. Preferred melt additives are methyl 7-oxooctadecanoate, cetyl alcohol, sodium thiosulphate, 4-(hydroxymethyl) benzoate, 4-phenylbutyric acid, 1,4-benzodioxan-6-carboxaldehyde, methyl 4-methoxybenzoate or 4-methylbenzhydrol. The reflective additive may be a salt of a transition metal, such as zinc dioxide, titanium dioxide or iron (III) oxide. The reflective additive may also be magnesium silicate or carbon black. The barrier cream may be coloured and the base cream is preferably aqueous, zinc, oil or glycerol based.
The gut microbiota, which is comprised of trillions of microbes, is the collective term for the gut microbiota. It establishes a symbiotic relationship with the host and plays a vital role in maintaining host health. Through training, the investigators can adjust the composition and functions of gut microbiota. Exercise also alters the body's energy metabolism pathways, which, in turn, impacts the gut microbiota and its metabolic products. Understanding how the body utilizes and regulates energy during exercise is essential for enhancing athletic performance. This study aims to explore the relationships among post-exercise energy metabolites, gut microbiota, and their metabolic products, applying omics technologies in the field of sports science.

This interdisciplinary research will contribute to fields such as exercise physiology, sports nutrition, exercise biochemistry, and sports medicine, providing innovative and practical research insights for advancing sports science in our country.
Virasal is for external use only. Do not permit Virasal to contact eyes or mucous membranes. If contact with eyes or mucous membranes occurs, immediately flush with water for 15 minutes. Virasal should not be allowed to contact normal skin surrounding wart, since localized irritation may occur. Treatment should be discontinued if excessive irritation occurs. Virasal is flammable. Keep away from fire or flame. Keep bottle tightly capped when not in use.
Elvitegravir and cobicistat, components of GENVOYA, are metabolized by CYP3A. Cobicistat is also metabolized, to a minor extent, by CYP2D6.

Drugs that induce CYP3A activity are expected to increase the clearance of elvitegravir and cobicistat, resulting in decreased plasma concentration of cobicistat, elvitegravir, and TAF, which may lead to loss of therapeutic effect of GENVOYA and development of resistance (see Table 5).

Coadministration of GENVOYA with other drugs that inhibit CYP3A may decrease the clearance and increase the plasma concentration of cobicistat. (see Table 5). TAF, a component of GENVOYA, is a substrate of P-gp, BCRP, OATP1B1 and OATP1B3. Drugs that inhibit P-gp and/or BCRP, such as cobicistat, may increase the absorption of TAF (see Table 13). However, when TAF is administered as a component of GENVOYA, its availability is increased by cobicistat and a further increase of TAF concentrations is not expected upon coadministration of an additional P-gp and/or BCRP inhibitor. Drugs that induce P-gp activity are expected to decrease the absorption of TAF, resulting in decreased plasma concentration of TAF.
A system is provided for determining a level of alertness of a subject, using a physiological sensor for providing physiological sensor signals which distinguish between a sleep state and an awake state of the subject. Sleep sessions are identified and their associated falling asleep and waking up times. A single representative midsleep time is obtained from multiple sleep sessions over a 24 hour period, and a circadian phase is estimated using the single representative midsleep time. A level of alertness is then obtained from the circadian phase. This system avoids the need for the use of a default circadian phase when determining a level of alertness. The system can more accurately estimate sleepiness for individuals that have irregular sleep patterns such as shift workers or people with sleep disorders. The single representative midsleep time is also able to take account of multiple sleep sessions, i.e. naps or periods of restless sleep.
Recent studies have shown that epithelial-mesenchymal transition (EMT) plays an important role in paraquat (PQ)-induced tissue fibrosis, which is the main cause of death in patients with PQ poisoning. However, no effective treatment for pulmonary interstitial fibrosis caused by PQ poisoning exists. It is of great significance for us to find new therapeutic targets through bioinformatics in PQ-induced EMT. We conducted transcriptome sequencing to determine the expression profiles of 1210 messenger RNAs (mRNAs), 558 long noncoding RNAs, 28 microRNAs (miRNAs), including 18 known-miRNAs, 10 novel-miRNAs and 154 circular RNAs in the PQ-exposed EMT group mice. Using gene ontology and Kyoto Encyclopaedia of Genes and Genomes analyses, we identified the pathways associated with signal transduction, cancers, endocrine systems and immune systems were involved in PQ-induced EMT. Furthermore, we constructed long noncoding RNA-miRNA-mRNA interrelated networks and found that upregulated genes included Il22ra2, Mdm4, Slc35e2 and Angptl4, and downregulated genes included RGS2, Gabpb2, Acvr1, Prkd3, Sp100, Tlr12, Syt15 and Camk2d. Thirteen new potential competitive endogenous RNA targets were also identified for further treatment of PQ-induced pulmonary tissue fibrosis. Through further study of the pathway and networks, we may identify new molecular targets in PQ-induced pulmonary EMT.